Biotech Values

[DewDiligence]

(ITMN) More dumbness in print from The Motley Fool—a perpetual source of such finds:

http://www.fool.com/investing/high-growth/2010/04/14/oops-this-drug-works-too-well.aspx

Top-line data from a phase 2b study of their hepatitis C drug danoprevir suggest that the drug works well -- when combined with Roche's Pegasys and Copegus, all three doses had cure rates near 90% compared with 43% for placebo.

Wrong! EVR, the metric cited above, is not a cure rate or even a proxy for such. You would think someone writing professionally about drugs for HCV would at least know the difference between EVR and SVR.